Icotinib hydrochloride (IH) is a small molecular TKI independently developed in China. As the first-line anti-tumor agent, is widely used for treatment of non-small cell lung cancer (NSCLC). Gallic acid (GA), a natural plant extract, is reported that it has a variety of pharmacological and biological properties. GA is a active natural phenolic extracted from Tannins that has been shown to exhibit anticancer activities on various types of tumors. Here, we reported that GA was capable of sensitizing A549/PC9 cells to IH by enhancing apoptosis. Mechanistic analyses indicated that IH-induced caspase-3-dependent apoptosis was elevated in the presence of GA through activating extracellular signal-regulated Hippo-YAP pathway. Furthermore, GA also promoted IH-induced cytotoxic, downregulated expression of p-YAP and caspase-3. In vivo, the co-treatment of IH and GA notably reduced the tumor size when compared with IH treatment alone. Notably, GA significantly reduced the toxicity generated by IH in tumor-bearing mice. This study identifies the unique role of GA enhance IH sensitivity through apoptosis, and suggests that combined IH and GA might be a novel therapeutic strategy for patients with NSCLC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.